NanoPhoria Bioscience — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

NanoPhoria Bioscience is an Italian preclinical biotech focused on revolutionizing cardiovascular drug delivery via its proprietary inhaled Nano-in-Micro platform. The company is targeting Heart Failure with Reduced Ejection Fraction (HFrEF), a condition with significant mortality and economic burden, where current systemic therapies leave substantial residual risk. Having secured Series A funding with participation from the European Innovation Council Fund, NanoPhoria is advancing its platform technology and pipeline programs toward clinical development. The company represents a novel approach aiming to improve efficacy and patient compliance through localized, non-invasive administration of therapeutics.

CardiovascularHeart Failure

Technology Platform

Proprietary inhaled Nano-in-Micro delivery platform built on inorganic Calcium Phosphate (CaP) nanoparticles, designed for precise, tissue-directed pulmonary delivery of therapeutics to cardiovascular targets.

Opportunities

The massive, growing, and underserved HFrEF market, with significant residual risk despite standard care, presents a prime opportunity for a novel delivery platform.

Success could establish a new paradigm in cardiology and create optionality to expand the inhaled Nano-in-Micro platform into other cardiovascular and pulmonary diseases.

Risk Factors

High technical risk associated with proving efficient cardiac targeting via pulmonary delivery and scaling a complex nanoparticle platform.

Clinical development risk is significant as the company has not yet entered human trials.

Intense competition from established and new systemic therapies in the crowded HFrEF landscape.

Competitive Landscape

Competes in the crowded HFrEF market against large pharma companies with entrenched oral and injectable therapies, as well as new drug classes and device-based interventions. Its primary differentiation is the novel inhaled delivery route, which, if proven, could circumvent limitations of systemic administration. Few, if any, competitors are pursuing inhaled delivery for primary cardiovascular targets.

More companies in Drug Delivery & Formulation →More companies in Italy →